Mirae Asset Global Investments
AARD icon

Mirae Asset Global Investments’s Aardvark Therapeutics AARD Stock Holding History

Mirae Asset Global Investments’s Portfolio AARD Stock Details AARD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.62K Sell
976
-160
-14% -$748 ﹤0.01% 1618
2026
Q1 		$4.28K Buy
1,136
+78
+7% +$809 ﹤0.01% 1532
2025
Q4 		$13.9K Buy
+1,058
New +$13.2K ﹤0.01% 1582

Other funds holding AARD

DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CF
Cantor Fitzgerald New York $9.31B AUM 73.66% 1-Year Est. Return

Mirae Asset Global Investments's AARD Position: Q2 2026 in Review

Mirae Asset Global Investments reduced its Aardvark Therapeutics (AARD) stake by 14% in Q2 2026, selling an estimated $748 and leaving 976 shares worth $5.62K. The position accounts for ﹤0.01% of the portfolio, ranked #1618.

Mirae Asset Global Investments first reported a position in AARD in Q4 2025 and has held it in 3 quarters since. The position peaked at $13.9K in Q4 2025. 71 funds tracked by Wall St. Rank hold AARD as of Q2 2026.

  • Mirae Asset Global Investments held 976 shares of Aardvark Therapeutics worth $5.62K as of Q2 2026.
  • Mirae Asset Global Investments sold 160 Aardvark Therapeutics shares in Q2 2026, an estimated $748.
  • Aardvark Therapeutics made up ﹤0.01% of Mirae Asset Global Investments's portfolio in Q2 2026, its #1618 holding.
  • Mirae Asset Global Investments first reported a position in Aardvark Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Mirae Asset Global Investments's Aardvark Therapeutics position peaked at $13.9K in Q4 2025.
  • 71 funds tracked by Wall St. Rank held Aardvark Therapeutics as of Q2 2026.

Based on Mirae Asset Global Investments's 13F filing for Q2 2026, filed 22 Jul 2026.